Table 2.
Tepotinib efficacy according to IRC (efficacy population).
| Treatment-naïve (n = 69) | Previously treated (n = 83) | Overall (N = 152) | |
|---|---|---|---|
| BOR, n (%) | |||
| CR | 0 | 0 | 0 |
| PR | 31 (44.9) | 37 (44.6) | 68 (44.7) |
| SD | 16 (23.2) | 23 (27.7) | 39 (25.7) |
| PD | 13 (18.8) | 13 (15.7) | 26 (17.1) |
| NE | 9 (13.0) | 10 (12.0) | 19 (12.5) |
| ORR, % | 44.9 | 44.6 | 44.7 |
| (95% CI) | (32.9–57.4) | (33.7–55.9) | (36.7–53.0) |
| DCR, % | 68.1 | 72.3 | 70.4 |
| (95% CI) | (55.8–78.8) | (61.4–81.6) | (62.5–77.5) |
| Median DOR, months | 10.8 | 11.1 | 11.1 |
| (95% CI) | (6.9–ne) | (9.5–18.5) | (8.4–18.5) |
| Median PFS, months | 8.5 | 10.9 | 8.9 |
| (95% CI) | (6.8–11.3) | (8.2–12.7) | (8.2–11.2) |
Abbreviation: DCR, disease control rate.